Boundless BioBOLD -3.54%14 PB Ratio is 0.64 as of Jun. 30, 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Boundless Bio ranks better than 92.03% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-30), Boundless Bio's share price is $2.455. Boundless Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $3.86. Hence, Boundless Bio's PB Ratio of today is 0.64.
The historical rank and industry rank for Boundless Bio's PB Ratio or its related term are showing as below:
BOLD'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.64
Current: 0.64
During the past 5 years, Boundless Bio's highest PB Ratio was 0.64. The lowest was 0.00. And the median was 0.00.
BOLD's PB Ratio is ranked better than 92.03% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs BOLD: 0.64
During the past 12 months, Boundless Bio's average Book Value Per Share Growth Rate was -34.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Boundless Bio PB Ratio Related Terms
Boundless Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Boundless Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Boundless Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Boundless Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Boundless Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Boundless Bio (BOLD) has a PB Ratio of 0.64 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Boundless Bio and its competitors. According to the industry distribution chart, Boundless Bio ranks #98 out of 1229 companies in the Biotechnology industry, placing it in the top 8%.
Is Boundless Bio's PB Ratio too high?
Boundless Bio's current PB Ratio is 0.64. The Biotechnology industry median PB Ratio is 2.86. Boundless Bio's value of 0.64 is 77.6% below this industry median. Based on the distribution chart, Boundless Bio ranks #98 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's PB Ratio compare to INKT and FLNA?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #98 out of 1229 companies for PB Ratio. This places Boundless Bio in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.86. Boundless Bio's value of 0.64 is 77.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boundless Bio's current PB Ratio of 0.64 is 77.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Boundless Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boundless Bio's current PB Ratio is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current PB Ratio of 0.64. The current PB Ratio is 0.64 and 77.6% below the Biotechnology industry median of 2.86. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Boundless Bio (BOLD), the current PB Ratio is 0.64 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
